Trial Profile
Phase 1 Study of U3-1287 -Assessment of the safety and pharmacokinetics of U3-1287 in patients with advanced solid tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Aug 2016
Price :
$35
*
At a glance
- Drugs Patritumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Daiichi Sankyo Company
- 15 Feb 2012 New trial record